# Nuo Therapeutics, Inc.: financial statements, quarterly

AURX · OTC · CIK 1091596 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aurx.md) · [Financials](/companies/aurx/financials.md) · [Filings](/companies/aurx/filings.md) · [Insiders](/companies/aurx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aurx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [232](/filings/0001437749-24-034325.md) | [197 d](/filings/0001437749-25-010379.md) | [235](/filings/0001437749-25-013653.md) | [365](/filings/0001437749-25-024043.md) | [371](/filings/0001437749-25-032437.md) | [395 d](/filings/0001437749-26-010360.md) | [484](/filings/0001437749-26-017104.md) | [700](/filings/0001437749-26-028053.md) | [1,032](/filings/0001437749-25-032437.md) | [1,097 d](/filings/0001437749-26-010360.md) | [1,302](/filings/0001437749-26-017104.md) | [1,769](/filings/0001437749-26-028053.md) |
| Cost of revenue | $k | [53.8](/filings/0001437749-24-034325.md) | [41.4 d](/filings/0001437749-25-010379.md) | [50.6](/filings/0001437749-25-013653.md) | [65.3](/filings/0001437749-25-024043.md) | [101](/filings/0001437749-25-032437.md) | [86.4 d](/filings/0001437749-26-010360.md) | [121](/filings/0001437749-26-017104.md) | [159](/filings/0001437749-26-028053.md) | [407](/filings/0001437749-25-032437.md) | [408 d](/filings/0001437749-26-010360.md) | [452](/filings/0001437749-26-017104.md) | [599](/filings/0001437749-26-028053.md) |
| Gross profit | $k | [178](/filings/0001437749-24-034325.md) | [156 d](/filings/0001437749-25-010379.md) | [184](/filings/0001437749-25-013653.md) | [299](/filings/0001437749-25-024043.md) | [270](/filings/0001437749-25-032437.md) | [308 d](/filings/0001437749-26-010360.md) | [363](/filings/0001437749-26-017104.md) | [541](/filings/0001437749-26-028053.md) | [625](/filings/0001437749-25-032437.md) | [688 d](/filings/0001437749-26-010360.md) | [850](/filings/0001437749-26-017104.md) | [1,170](/filings/0001437749-26-028053.md) |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $k | [968](/filings/0001437749-24-034325.md) | [808 d](/filings/0001437749-25-010379.md) | [893](/filings/0001437749-25-013653.md) | [841](/filings/0001437749-25-024043.md) | [848](/filings/0001437749-25-032437.md) | [938 d](/filings/0001437749-26-010360.md) | [1,109](/filings/0001437749-26-017104.md) | [1,193](/filings/0001437749-26-028053.md) | [1,166](/filings/0001437749-25-032437.md) | [1,268 d](/filings/0001437749-26-010360.md) | [1,296](/filings/0001437749-26-017104.md) | [1,337](/filings/0001437749-26-028053.md) |
| Operating income | $k | [(790)](/filings/0001437749-24-034325.md) | [(652) d](/filings/0001437749-25-010379.md) | [(709)](/filings/0001437749-25-013653.md) | [(542)](/filings/0001437749-25-024043.md) | [(577)](/filings/0001437749-25-032437.md) | [(629) d](/filings/0001437749-26-010360.md) | [(745)](/filings/0001437749-26-017104.md) | [(652)](/filings/0001437749-26-028053.md) | [(540)](/filings/0001437749-25-032437.md) | [(579) d](/filings/0001437749-26-010360.md) | [(446)](/filings/0001437749-26-017104.md) | [(167)](/filings/0001437749-26-028053.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(791)](/filings/0001437749-24-034325.md) | [(653) d](/filings/0001437749-25-010379.md) | [(709)](/filings/0001437749-25-032437.md) | [(540)](/filings/0001437749-25-032437.md) | [(578)](/filings/0001437749-25-032437.md) | [(497) d](/filings/0001437749-26-010360.md) | [(746)](/filings/0001437749-26-028053.md) | [(650)](/filings/0001437749-26-028053.md) | [(538)](/filings/0001437749-25-032437.md) | [(578) d](/filings/0001437749-26-010360.md) | [(618)](/filings/0001437749-26-028053.md) | [(278)](/filings/0001437749-26-028053.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.02)](/filings/0001437749-24-034325.md) | not reported | [(0.02)](/filings/0001437749-25-013653.md) | [(0.01)](/filings/0001437749-25-024043.md) | [(0.01)](/filings/0001437749-25-032437.md) | not reported | [(0.02)](/filings/0001437749-26-017104.md) | [(0.01)](/filings/0001437749-26-028053.md) | [(0.01)](/filings/0001437749-25-032437.md) | not reported | [(0.01)](/filings/0001437749-26-017104.md) | [(0.01)](/filings/0001437749-26-028053.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [583](/filings/0001437749-24-034325.md) | [929](/filings/0001437749-25-010379.md) | [366](/filings/0001437749-24-017125.md) | [473](/filings/0001437749-24-025952.md) | [684](/filings/0001437749-24-034325.md) | [284](/filings/0001437749-26-010360.md) | [55.7](/filings/0001437749-25-013653.md) | [316](/filings/0001437749-25-024043.md) | [515](/filings/0001437749-25-032437.md) | [549](/filings/0001437749-26-028053.md) | [264](/filings/0001437749-26-017104.md) | [449](/filings/0001437749-26-028053.md) |
| Current assets | $k | [1,258](/filings/0001437749-23-032632.md) | [1,563](/filings/0001437749-25-010379.md) | [981](/filings/0001437749-24-017125.md) | [1,175](/filings/0001437749-24-025952.md) | [1,343](/filings/0001437749-24-034325.md) | [842](/filings/0001437749-26-010360.md) | [602](/filings/0001437749-25-013653.md) | [853](/filings/0001437749-25-024043.md) | [1,463](/filings/0001437749-25-032437.md) | [1,380](/filings/0001437749-26-028053.md) | [1,520](/filings/0001437749-26-017104.md) | [1,993](/filings/0001437749-26-028053.md) |
| Total assets | $k | [1,600](/filings/0001437749-23-032632.md) | [1,878](/filings/0001437749-25-010379.md) | [1,243](/filings/0001437749-24-017125.md) | [1,420](/filings/0001437749-24-025952.md) | [1,719](/filings/0001437749-24-034325.md) | [1,190](/filings/0001437749-26-010360.md) | [1,147](/filings/0001437749-25-013653.md) | [1,359](/filings/0001437749-25-024043.md) | [1,928](/filings/0001437749-25-032437.md) | [1,846](/filings/0001437749-26-028053.md) | [1,946](/filings/0001437749-26-017104.md) | [2,626](/filings/0001437749-26-028053.md) |
| Current liabilities | $k | [685](/filings/0001437749-23-032632.md) | [675](/filings/0001437749-25-010379.md) | [761](/filings/0001437749-24-017125.md) | [690](/filings/0001437749-24-025952.md) | [714](/filings/0001437749-24-034325.md) | [578](/filings/0001437749-26-010360.md) | [1,281](/filings/0001437749-25-013653.md) | [999](/filings/0001437749-25-024043.md) | [1,256](/filings/0001437749-25-032437.md) | [1,306](/filings/0001437749-26-028053.md) | [1,369](/filings/0001437749-26-017104.md) | [1,554](/filings/0001437749-26-028053.md) |
| Total liabilities | $k | [873](/filings/0001437749-23-032632.md) | [839](/filings/0001437749-25-010379.md) | [909](/filings/0001437749-24-017125.md) | [822](/filings/0001437749-24-025952.md) | [829](/filings/0001437749-24-034325.md) | [676](/filings/0001437749-26-010360.md) | [1,360](/filings/0001437749-25-013653.md) | [2,184](/filings/0001437749-25-024043.md) | [2,347](/filings/0001437749-25-032437.md) | [2,802](/filings/0001437749-26-028053.md) | [3,330](/filings/0001437749-26-017104.md) | [4,162](/filings/0001437749-26-028053.md) |
| Long-term debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [727](/filings/0001437749-24-034325.md) | [1,039](/filings/0001437749-26-010360.md) | [333](/filings/0001437749-25-032437.md) | [599](/filings/0001437749-25-032437.md) | [890](/filings/0001437749-25-032437.md) | [514](/filings/0001437749-26-028053.md) | [(213)](/filings/0001437749-26-028053.md) | [(825)](/filings/0001437749-26-028053.md) | [(420)](/filings/0001437749-25-032437.md) | [(957)](/filings/0001437749-26-028053.md) | [(1,384)](/filings/0001437749-26-028053.md) | [(1,535)](/filings/0001437749-26-028053.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(795) d](/filings/0001437749-24-034325.md) | [(671) d](/filings/0001437749-25-010379.md) | [(562)](/filings/0001437749-25-013653.md) | [(691) d](/filings/0001437749-25-024043.md) | [(487) d](/filings/0001437749-25-032437.md) | [(491) d](/filings/0001437749-26-010360.md) | [1.8](/filings/0001437749-26-017104.md) | [262 d](/filings/0001437749-26-028053.md) | [(707) d](/filings/0001437749-25-032437.md) | [(423) d](/filings/0001437749-26-010360.md) | [(784)](/filings/0001437749-26-017104.md) | [(236) d](/filings/0001437749-26-028053.md) |
| Capital expenditure | $k | [1.9 d](/filings/0001437749-24-034325.md) | [0.0 d](/filings/0001437749-25-010379.md) | [0.0](/filings/0001437749-25-013653.md) | [4.1 d](/filings/0001437749-25-024043.md) | [151 d](/filings/0001437749-25-032437.md) | [0.0 d](/filings/0001437749-26-010360.md) | [230](/filings/0001437749-26-017104.md) | [1.7 d](/filings/0001437749-26-028053.md) | [0.0 d](/filings/0001437749-25-032437.md) | [43.2 d](/filings/0001437749-26-010360.md) | [0.8](/filings/0001437749-26-017104.md) | [253 d](/filings/0001437749-26-028053.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2018 (2018-03-31) | Q2 FY2018 (2018-06-30) | Q3 FY2018 (2018-09-30) | Q1 FY2019 (2019-03-31) | Q2 FY2019 (2019-06-30) | Q3 FY2019 (2019-09-30) | period not labelled (2020-03-31) | period not labelled (2020-06-30) | period not labelled (2020-09-30) | period not labelled (2021-03-31) | period not labelled (2021-06-30) | Q3 FY2021 (2021-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.7](/filings/0001437749-19-010509.md) | [22.9](/filings/0001437749-19-017108.md) | [23.7](/filings/0001437749-20-001481.md) | [23.7](/filings/0001437749-19-010509.md) | [23.7](/filings/0001437749-19-017108.md) | [23.7](/filings/0001437749-20-001481.md) | [30.5](/filings/0001437749-22-009050.md) | [24.2](/filings/0001437749-22-009050.md) | [24.2](/filings/0001437749-22-009050.md) | [30.3](/filings/0001437749-22-009050.md) | [30.3](/filings/0001437749-22-009050.md) | [30.3](/filings/0001437749-22-009050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,433,777 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-028053.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.